Odevixibat-d5

Odevixibat-d5 is deuterated labeled Odevixibat (HY-109120) . Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis[1].

Product Specifications

Product Name Alternative

A4250-d5

UNSPSC

12352005

Target

Apical Sodium-Dependent Bile Acid Transporter; Isotope-Labeled Compounds

Type

Isotope-Labeled Compounds

Related Pathways

Membrane Transporter/Ion Channel; Others

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Solubility

10 mM in DMSO

Smiles

[2H]C1=C(C([2H])=C(C([2H])=C1[2H])N2CC(CCCC)(NS(=O)(C3=CC(OCC(N[C@H](C4=CC=C(C=C4)O)C(N[C@H](C(O)=O)CC)=O)=O)=C(C=C32)SC)=O)CCCC)[2H]

Molecular Formula

C37H43D5N4O8S2

Molecular Weight

745.96

References & Citations

[1]Baghdasaryan A, et al. Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis.J Hepatol. 2016 Mar;64 (3) :674-81.|[2]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.